



PerkinElmer and EverlyWell Announce Collaboration to Expand U.S. At-Home Health Test Market

July 24, 2019

Combines PerkinElmer's expertise in immunodiagnostic testing and state-of-the-art genomics program with EverlyWell's consumer health offerings

WALTHAM, Massachusetts, and AUSTIN, Texas – July 24, 2019 – Today, [PerkinElmer, Inc.](#) and [EverlyWell, Inc.](#) announced a new collaboration designed to accelerate innovation in and accessibility of consumer-initiated health testing, by adding PerkinElmer's CLIA-certified and CAP-accredited lab facilities to EverlyWell's network of laboratory providers.

"Consumer-driven healthcare continues to make inroads into lab testing and diagnostics, as more patients are empowered to take control of their health management with trusted partners like EverlyWell," said Dr. Madhuri Hegde, Ph.D., FACMG, chief scientific officer at [PerkinElmer Genomics](#). "Clinicians around the world rely on PerkinElmer's state-of-the-art clinical genomics program, plus autoimmune, allergy and molecular genetic testing capabilities. Now, through EverlyWell's marketplace, consumers will be able to access these clinical-grade services conveniently from home."

The first offerings resulting from this collaboration are [Lyme disease](#) and [food sensitivity](#) tests, for which PerkinElmer provides the expertise behind EverlyWell's panels. Both tests employ dried blood spot testing—a method that has been used for decades by doctors and hospitals to identify disease biomarkers with only a few drops of blood—and were developed by board-certified medical geneticists at PerkinElmer Genomics, then validated on the [EUROIMMUN EUROBlotOne® system](#) and [EUROIMMUN Analyzer™ systems](#)

PerkinElmer has long been recognized as a worldwide leader in dried blood spot testing, notably in its industry-leading work with [newborn screening](#). Over 600 million newborn babies worldwide have been screened for life-threatening diseases using PerkinElmer's dried blood spot testing solution. PerkinElmer's [EUROIMMUN products](#) are also widely recognized as expert solutions for autoimmune, infectious disease, allergy and molecular genetic testing.

Together, the two companies will work to expand EverlyWell's test menu, bringing additional panels to market.

"PerkinElmer has been one of the foremost global authorities in medical and scientific innovation and diagnostics for over 80 years. We could not be more thrilled to have this collaboration with them," said Julia Cheek, EverlyWell founder and CEO. "Already, hundreds of thousands of people have trusted EverlyWell to better understand their health, with our customer base tripling every year. As we continue to expand our reach, we need best-in-class laboratory partners like PerkinElmer to ensure we can scale to meet demand while continuing to provide an unmatched customer experience."

EverlyWell provides consumers with access to a [wide selection](#) of physician-ordered and -reviewed laboratory tests that start at \$49. Once a test is purchased online, or at select Target or CVS locations nationwide, samples are collected by the customer and sent by mail to an independent, CLIA-certified laboratory. Independent physicians review every test order and the results of each test, which are available to the customer within days.

For diagnostic tests, such as EverlyWell's Lyme disease test, independent physicians are available to consult with customers whose results indicate infection and may prescribe treatment based on the test results and medical history. Customers who take non-diagnostic tests have the option to discuss their results with one of EverlyWell's licensed health professionals.

For more information, contact:

Brian Willinsky
Global Public Relations Leader, PerkinElmer
brian.willinsky@perkinelmer.com
PR@perkinelmer.com

Christina Song
Director of Communications, EverlyWell
csong@everlywell.com
media@everlywell.com

About PerkinElmer

PerkinElmer enables scientists, researchers and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, we deliver unique solutions to serve the diagnostics, life sciences, food and applied markets. We strategically partner with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise. Our dedicated team of about 13,000 employees worldwide is passionate about helping customers work to create healthier families, improve the quality of life, and sustain the wellbeing and longevity of people globally. The Company reported revenue of approximately \$2.8 billion in 2018, serves customers in more than 180 countries, and is a component of the S&P 500 index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.

About EverlyWell

EverlyWell believes consumers deserve access to affordable lab tests and insightful, digitally-enabled results with actionable next steps. The company

connects consumers to lab partners offering a suite of validated lab tests including Food Sensitivity, Fertility and Women's Hormones, STDs, and Thyroid. Prices are straightforward starting at \$49 and are generally covered by Flexible Spending and Health Savings Accounts. Physician-reviewed, actionable test results from CLIA-certified labs are provided within days of sample receipt.

The company was founded in 2015, is located in Austin, TX and backed by notable investors including Goodwater Capital, Highland Capital Partners, Next Coast Ventures, NextGen Venture Partners, among others. EverlyWell was selected as one of Fast Company's Most Innovative Companies in 2019.

For more information please visit www.everlywell.com.